Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KCB-200
- Development stage
- Unknown
- Lead developer
- Kapoose Creek Bio
- Modality
- Small Molecules
01
Overview
KCB-200 is a small molecule drug candidate developed by Kapoose Creek Bio for neurological indications. It is derived from the company’s proprietary collection of cultured and preserved fungi, primarily sourced from the biodiverse ecosystem of the Kapoose Creek rainforest on Vancouver Island. Preclinical data indicate that KCB-200 exhibits potent neuroplastic and neuroprotective activity in gold-standard tests of primary neurons. The compound is being advanced using AI-powered technology for potential clinical development in neurology, with depressive disorder as an active indication under investigation[7][10].
Beyond the preview
Go deeper on KCB-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KCB-200.